Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

NCT02966730 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Follicular Lymphoma
Follicular Lymphoma, Grade 1
Follicular Lymphoma, Grade 2
Follicular Lymphoma Grade IIIa

Interventions

DRUG: Ibrutinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]